Abbott and Tidepool Partnership; New Retatrutide Obesity Trial; Apple Prediabetes App
Here is a brief preview of this blast: Three cardiometabolic-related news items have been observed: Abbott and Tidepool announced a cloud-to-cloud integration partnership (view press release); Lilly initiated a retatrutide study in obesity (view CT.gov record); and Apple initiated development of a prediabetes app (view article). Below, FENIX provides highlights and insights for the respective news items.